https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Immunol. 2008 Jul;181(1):808-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Immunol. 2008 Jul;181(1):808-212008-07-01 00:00:002008-07-01 00:00:00Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Curr Opin Oncol 2008 Jul;20(4):438-43
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Curr Opin Oncol 2008 Jul;20(4):438-432008-07-01 00:00:002008-07-01 00:00:00Regional hyperthermia in high-risk soft tissue sarcomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Expert Opin Biol Ther 2008 Jul;8(7):865-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Expert Opin Biol Ther 2008 Jul;8(7):865-742008-07-01 00:00:002019-02-15 08:44:34Maximizing dendritic cell migration in cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Int J Immunopathol Pharmacol 2008 Jul-Sep;21(3):493-500
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Int J Immunopathol Pharmacol 2008 Jul-Sep;21(3):493-5002008-07-01 00:00:002019-02-15 09:19:20Strategies to overcome obstacles to successful immunotherapy of melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-512008-07-01 00:00:002019-02-15 09:19:24Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-412008-07-01 00:00:002019-02-15 09:19:25Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-27 / BMC Immunol. 2008 Jun;9:32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-27 / BMC Immunol. 2008 Jun;9:322008-06-27 00:00:002019-02-15 08:50:17Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-17 / J. Leukoc. Biol. 2008 Oct;84(4):981-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-17 / J. Leukoc. Biol. 2008 Oct;84(4):981-72008-06-17 00:00:002019-02-15 08:38:03The essential role of the in situ immune reaction in human colorectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-16 / Int. J. Urol. 2008 Aug;15(8):694-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-16 / Int. J. Urol. 2008 Aug;15(8):694-82008-06-16 00:00:002019-02-15 08:48:09Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-06 / Cancer Gene Ther. 2008 Dec;15(12):795-807
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-06 / Cancer Gene Ther. 2008 Dec;15(12):795-8072008-06-06 00:00:002008-06-06 00:00:00Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors
